多发性骨髓瘤骨髓微环境与免疫治疗的交互作用：机制、挑战与前景
The Interaction between the Bone Marrow Microenvironment and Immunotherapy in Multiple Myeloma: Mechanisms, Challenges, and Prospects
DOI: 10.12677/acm.2025.1541037, PDF,   
作者: 张慧敏：内蒙古医科大学鄂尔多斯临床医学院，内蒙古 鄂尔多斯；赛音其木格：鄂尔多斯市中心医院血液内科，内蒙古 鄂尔多斯
关键词: 多发性骨髓瘤；骨髓微环境；免疫治疗；Multiple Myeloma； Bone Marrow Microenvironment； Immunotherapy
摘要: 现阶段多发性骨髓瘤仍是一种无法治愈的疾病。近年来，以CD38单克隆抗体为代表的免疫治疗药物在临床中的应用显著延长了MM患者的生存时间。同时嵌合抗原受体(CAR-T细胞)和双特异性抗体(BsAbs)等新型免疫治疗手段的不断发展，正在逐步改变MM的治疗格局。然而免疫治疗在MM中的应用仍面临诸多挑战，例如肿瘤细胞的高度异质性、骨髓微环境的免疫抑制以及代谢相关障碍等问题。未来的研究和治疗策略需要进一步优化，通过联合靶向骨髓微环境和免疫调节，提升免疫治疗的疗效和安全性，从而为骨髓瘤患者争取更好的预后。
Abstract: Multiple myeloma (MM) remains an incurable disease. In recent years, the clinical application of immune therapies, particularly CD38 monoclonal antibodies, has significantly extended the survival of MM patients. Additionally, the emergence of innovative immunotherapies, such as chimeric antigen receptor (CAR-T) cells and bispecific antibodies (BsAbs), is reshaping the treatment paradigm of MM. However, significant challenges persist in the application of immunotherapy for MM, including tumor heterogeneity, the immunosuppressive bone marrow microenvironment, and metabolic dysregulation. Moving forward, optimizing treatment strategies that integrate targeting of the bone marrow microenvironment with immune modulation may further enhance the efficacy and safety of immunotherapies, ultimately improving outcomes for MM patients.
文章引用：张慧敏, 赛音其木格. 多发性骨髓瘤骨髓微环境与免疫治疗的交互作用：机制、挑战与前景[J]. 临床医学进展, 2025, 15(4): 1122-1130. https://doi.org/10.12677/acm.2025.1541037

参考文献

[1] Alexander, D.D., Mink, P.J., Adami, H., Cole, P., Mandel, J.S., Oken, M.M., et al. (2007) Multiple Myeloma: A Review of the Epidemiologic Literature. International Journal of Cancer, 120, 40-61. [Google Scholar] [CrossRef] [PubMed]
[2] Malard, F., Neri, P., Bahlis, N.J., Terpos, E., Moukalled, N., Hungria, V.T.M., et al. (2024) Multiple Myeloma. Nature Reviews Disease Primers, 10, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[3] Giannakoulas, N., Ntanasis-Stathopoulos, I. and Terpos, E. (2021) The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. International Journal of Molecular Sciences, 22, Article 4462. [Google Scholar] [CrossRef] [PubMed]
[4] Fairfield, H., Falank, C., Avery, L. and Reagan, M.R. (2016) Multiple Myeloma in the Marrow: Pathogenesis and Treatments. Annals of the New York Academy of Sciences, 1364, 32-51. [Google Scholar] [CrossRef] [PubMed]
[5] Minnie, S.A. and Hill, G.R. (2020) Immunotherapy of Multiple Myeloma. Journal of Clinical Investigation, 130, 1565-1575. [Google Scholar] [CrossRef] [PubMed]
[6] Binder, M., Szalat, R.E., Talluri, S., Fulciniti, M., Avet-Loiseau, H., Parmigiani, G., et al. (2024) Bone Marrow Stromal Cells Induce Chromatin Remodeling in Multiple Myeloma Cells Leading to Transcriptional Changes. Nature Communications, 15, Article No. 4139. [Google Scholar] [CrossRef] [PubMed]
[7] Schütt, J., Nägler, T., Schenk, T. and Brioli, A. (2021) Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers, 13, Article 4069. [Google Scholar] [CrossRef] [PubMed]
[8] Gunes, E.G., Rosen, S.T. and Querfeld, C. (2020) The Role of Myeloid-Derived Suppressor Cells in Hematologic Malignancies. Current Opinion in Oncology, 32, 518-526. [Google Scholar] [CrossRef] [PubMed]
[9] Hezaveh, K., Shinde, R.S., Klötgen, A., Halaby, M.J., Lamorte, S., Ciudad, M.T., et al. (2022) Tryptophan-Derived Microbial Metabolites Activate the Aryl Hydrocarbon Receptor in Tumor-Associated Macrophages to Suppress Anti-Tumor Immunity. Immunity, 55, 324-340.e8. [Google Scholar] [CrossRef] [PubMed]
[10] Su, Y., Banerjee, S., White, S.V. and Kortylewski, M. (2018) STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity. International Journal of Molecular Sciences, 19, Article 1803. [Google Scholar] [CrossRef] [PubMed]
[11] Glavey, S.V., Naba, A., Manier, S., Clauser, K., Tahri, S., Park, J., et al. (2017) Proteomic Characterization of Human Multiple Myeloma Bone Marrow Extracellular Matrix. Leukemia, 31, 2426-2434. [Google Scholar] [CrossRef] [PubMed]
[12] Ho, M., Dasari, S., Visram, A., Drake, M.T., Charlesworth, M.C., Johnson, K.L., et al. (2023) An Atlas of the Bone Marrow Bone Proteome in Patients with Dysproteinemias. Blood Cancer Journal, 13, Article No. 63. [Google Scholar] [CrossRef] [PubMed]
[13] Xu, Y., Guo, J., Liu, J., Xie, Y., Li, X., Jiang, H., et al. (2021) Hypoxia-Induced CREB Cooperates MMSET to Modify Chromatin and Promote DKK1 Expression in Multiple Myeloma. Oncogene, 40, 1231-1241. [Google Scholar] [CrossRef] [PubMed]
[14] Parrondo, R.D., Ailawadhi, S. and Cerchione, C. (2024) Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives. Frontiers in Oncology, 14, Article 1394048. [Google Scholar] [CrossRef] [PubMed]
[15] Bhutani, M., Robinson, M., Foureau, D., Atrash, S., Paul, B., Guo, F., et al. (2025) MRD-Driven Phase 2 Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood Advances, 9, 507-519. [Google Scholar] [CrossRef] [PubMed]
[16] Brinkmann, U. and Kontermann, R.E. (2021) Bispecific Antibodies. Science, 372, 916-917. [Google Scholar] [CrossRef] [PubMed]
[17] Devasia, A.J., Chari, A. and Lancman, G. (2024) Bispecific Antibodies in the Treatment of Multiple Myeloma. Blood Cancer Journal, 14, Article No. 158. [Google Scholar] [CrossRef] [PubMed]
[18] Cohen, Y.C., Magen, H., Gatt, M., Sebag, M., Kim, K., Min, C., et al. (2025) Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 392, 138-149. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, Z., Chen, C., Wang, L., Jia, Y. and Qin, Y. (2022) Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Frontiers in Immunology, 13, Article 1050522. [Google Scholar] [CrossRef] [PubMed]
[20] Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., et al. (2024) CAR T Therapies in Multiple Myeloma: Unleashing the Future. Cancer Gene Therapy, 31, 667-686. [Google Scholar] [CrossRef] [PubMed]
[21] Swan, D., Madduri, D. and Hocking, J. (2024) CAR-T Cell Therapy in Multiple Myeloma: Current Status and Future Challenges. Blood Cancer Journal, 14, Article No. 206. [Google Scholar] [CrossRef] [PubMed]
[22] Zhou, D., Sun, Q., Xia, J., Gu, W., Qian, J., Zhuang, W., et al. (2024) Anti-BCMA/GPRC5D Bispecific CAR T Cells in Patients with Relapsed or Refractory Multiple Myeloma: A Single-Arm, Single-Centre, Phase 1 Trial. The Lancet Haematology, 11, e751-e760. [Google Scholar] [CrossRef] [PubMed]
[23] Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A.L., Ortolan, E., et al. (2008) Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiological Reviews, 88, 841-886. [Google Scholar] [CrossRef] [PubMed]
[24] Horenstein, A.L., Faini, A.C., Morandi, F., Ortolan, E., Storti, P., Giuliani, N., et al. (2025) Monoclonal Anti-CD38 Therapy in Human Myeloma: Retrospects and Prospects. Frontiers in Immunology, 16, Article 1519300. [Google Scholar] [CrossRef] [PubMed]
[25] Franssen, L.E., Stege, C.A.M., Zweegman, S., van de Donk, N.W.C.J. and Nijhof, I.S. (2020) Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma. Journal of Clinical Medicine, 9, Article 1195. [Google Scholar] [CrossRef] [PubMed]
[26] Iversen, K.F. (2024) Mechanisms of Resistance to Daratumumab in Patients with Multiple Myeloma. Basic & Clinical Pharmacology & Toxicology, 135, 401-408. [Google Scholar] [CrossRef] [PubMed]
[27] Firestone, R.S., Socci, N.D., Shekarkhand, T., Zhu, M., Qin, W.G., Hultcrantz, M., et al. (2024) Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma. Blood, 144, 402-407. [Google Scholar] [CrossRef] [PubMed]
[28] Tsyklauri, O., Chadimova, T., Niederlova, V., Kovarova, J., Michalik, J., Malatova, I., et al. (2023) Regulatory T Cells Suppress the Formation of Potent KLRK1 and IL-7R Expressing Effector CD8 T Cells by Limiting Il-2. eLife, 12, e79342. [Google Scholar] [CrossRef] [PubMed]
[29] Kawano, Y. (2021) The Role of Regulatory T Cells in Multiple Myeloma Progression. The Japanese Journal of Clinical Hematology, 62, 299-304.
[30] Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., et al. (2024) Reshaping the Tumor Immune Microenvironment to Improve CAR-T Cell-Based Cancer Immunotherapy. Molecular Cancer, 23, Article No. 175. [Google Scholar] [CrossRef] [PubMed]
[31] Sklavenitis-Pistofidis, R., Aranha, M.P., Redd, R.A., et al. (2022) Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. Cancer Cell, 40, 1358-1373. e8.
[32] Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., Lim, L., et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells against Multiple Myeloma. Clinical Cancer Research, 24, 106-119. [Google Scholar] [CrossRef] [PubMed]
[33] Leone, R.D. and Powell, J.D. (2020) Metabolism of Immune Cells in Cancer. Nature Reviews Cancer, 20, 516-531. [Google Scholar] [CrossRef] [PubMed]
[34] Barbato, A., Giallongo, C., Giallongo, S., Romano, A., Scandura, G., Concetta, S., et al. (2023) Lactate Trafficking Inhibition Restores Sensitivity to Proteasome Inhibitors and Orchestrates Immuno‐Microenvironment in Multiple Myeloma. Cell Proliferation, 56, e13388. [Google Scholar] [CrossRef] [PubMed]
[35] Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., et al. (2021) The Regulation of Immune Checkpoints by the Hypoxic Tumor Microenvironment. PeerJ, 9, e11306. [Google Scholar] [CrossRef] [PubMed]
[36] Jacobson, C.A., Westin, J.R., Miklos, D.B., Herrera, A.F., Lee, J., Seng, J., et al. (2020) Abstract CT055: Phase 1/2 Primary Analysis of ZUMA-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab (Atezo) for the Treatment of Patients (Pts) with Refractory Diffuse Large B Cell Lymphoma (DLBCL). Cancer Research, 80, CT055. [Google Scholar] [CrossRef] 
[37] Sidana, S., Patel, K.K., Peres, L.C., Bansal, R., Kocoglu, M.H., Shune, L., et al. (2025) Safety and Efficacy of Standard-of-Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood, 145, 85-97. [Google Scholar] [CrossRef] [PubMed]
[38] Bernabei, L., Garfall, A.L., Melenhorst, J.J., Lacey, S.F., Stadtmauer, E.A., Vogl, D.T., et al. (2018) PD-1 Inhibitor Combinations as Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after BCMA-Directed CAR T Cells. Blood, 132, 1973-1973. [Google Scholar] [CrossRef] 
[39] Munshi, N.C. and Anderson, K.C. (2013) Minimal Residual Disease in Multiple Myeloma. Journal of Clinical Oncology, 31, 2523-2526. [Google Scholar] [CrossRef] [PubMed]

为你推荐